New painkiller designed to replace off-label use of Actiq, Fentora

posted on:
February 24, 2010


Drug maker Javelin hopes to meet with the Food and Drug Administration (FDA) to discuss approval of its new painkiller, Ereska. The drug is a non-opioid nasal medication designed to treat moderate to severe pain and provide physicians with an accepted and regulated alternative to off-label use and opioids.

Ereska is a formulation of ketamine, an anesthetic and analgesic that is also known on the streets as a “date rape” drug. It is well positioned to compete against Cephalon’s opioids Actiq and Fentora for breakthrough pain in cancer patients who have built up a resistance to opioids.

A 2007 study found Cephalon’s painkillers were most often used for the treatment of migraines and backaches, a use that is not approved by the FDA and found to cause serious adverse events in patients who have not already built up a tolerance to opioids. Javelin hopes Ereska will serve as an FDA-approved alternative for doctors and their patients seeking treatment for pain.

The world of painkillers is especially treacherous for drug makers, who have to tackle issues of narcotics abuse and safety issues with their products. Off-label use of Actiq and the more potent Fentora have been linked to fatal respiratory complications and associated with 127 deaths and 91 incidences of severe side effects.

Javelin’s Ereska may serve as a safer alternative; however, it isn’t foolproof. Phase III clinical trials for Ereska showed myriad hallucinatory and other psychomimetic effects in healthy volunteers taking sub-anesthetic doses of the drug, an issue that raises safety concerns among pain specialists.

Source: Behavioral Health Central 

Free Legal Consultation
At Beasley Allen, there is never a fee for legal services, unless we collect for you. Contact us today by filling out a brief questionnaire, or by calling our toll free number, 1-800-898-2034, for a free, no-cost no-obligation evaluation of your case.
back to top